QL1706 + celecoxib

This drug is a **combination therapy** of QL1706, a bifunctional antibody targeting **PD-1 (programmed cell death protein 1)** and **CTLA-4 (cytotoxic T-lymphocyte antigen 4)**, and **celecoxib**, a selective **COX-2 (cyclooxygenase-2) inhibitor**. - **QL1706** is a novel dual immune checkpoint inhibitor; it contains a mixture of anti-PD-1 (IgG4) and anti-CTLA-4 (IgG1) antibodies, manufactured using a single cell line. It is designed to enhance antitumor immunity by blocking two key immune checkpoint pathways. The anti-CTLA-4 antibody in QL1706 is engineered for reduced half-life, allowing more nuanced immune modulation[2][4][6][8]. - **Celecoxib** is a well-established small molecule anti-inflammatory drug, acting by inhibiting COX-2 and thereby reducing prostaglandin synthesis. In oncology, celecoxib may have direct and indirect antitumor effects, including reducing tumor-promoting inflammation. The combination is currently under investigation for patients with advanced esophageal squamous cell carcinoma (ESCC), particularly those refractory to immune checkpoint inhibitors[1][3][9]. QL1706 is developed by Qilu Pharmaceutical. Celecoxib is marketed as Celebrex by Pfizer.

Other names

QL1706 plus celecoxibQL-1706 plus celecoxibQL 1706 plus celecoxib